Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs

Biochemical and Biophysical Research Communications

Volumn 410, Issue 4, 2011, Pages 707-713

  Bourgault, Steve ^a   Choi, Sungwook ^a,b   Buxbaum, Joel N ^a   Kelly, Jeffery W ^a   Price, Joshua L ^a   Reixach, Natàlia ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b Chungnam National University   (South Korea)

Author keywords

Amyloid; Cardiomyopathy; Cytotoxicity; Protein misfolding; Resveratrol; Transthyretin

Indexed keywords

DIHYDROSTILBENE; PREALBUMIN; RESVERATROL; RESVERATROL ESTER DERIVATIVE; RESVERATROL THIOESTER DERIVATIVE; STILBENE DERIVATIVE; TETRAMER; UNCLASSIFIED DRUG;

ARTICLE; CARDIOTOXICITY; CELL METABOLISM; CONTROLLED STUDY; CYTOTOXICITY; DRUG BINDING; DRUG SCREENING; DRUG STRUCTURE; FIBER; HEART; HEART AMYLOIDOSIS; HEART MUSCLE CELL; HEART PROTECTION; HUMAN; HUMAN CELL; KINETICS; PRIORITY JOURNAL; TISSUE CULTURE;

AMYLOIDOSIS; ANTIOXIDANTS; CELL LINE; HUMANS; MYOCYTES, CARDIAC; PREALBUMIN; STILBENES;

EID: 79960291244     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.04.133     Document Type: Article

References (36)

1. Buxbaum J.N. The amyloidoses. Rheumatology 2008, 1671-1681. Elsevier, London. M.C. Hochberg, A.J. Silman, J.S. Smolen, M.E. Weinblatt, M.H. Weisman (Eds.).
2. Buxbaum J.N. The systemic amyloidoses. Curr. Opin. Rheumatol. 2004, 16:67-75.
3. Westermark P., Benson M.D., Buxbaum J.N., Cohen A.S., Frangione B., Ikeda S., Masters C.L., Merlini G., Saraiva M.J., Sipe J.D. A primer of amyloid nomenclature. Amyloid 2007, 14:179-183.
4. Baures P.W., Peterson S.A., Kelly J.W. Discovering transthyretin amyloid fibril inhibitors by limited screening. Bioorg. Med. Chem. 1998, 6:1389-1401.
5. Buxbaum J.N., Ye Z., Reixach N., Friske L., Levy C., Das P., Golde T., Masliah E., Roberts A.R., Bartfai T. Transthyretin protects Alzheimer's mice from the behavioral and biochemical effects of Abeta toxicity. Proc. Natl. Acad. Sci. USA 2008, 105:2681-2686.
6. Buxbaum J.N., Reixach N. Transthyretin: the servant of many masters. Cell. Mol. Life Sci. 2009, 66:3095-3101.
7. Kelly J.W. The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways. Curr. Opin. Struct. Biol. 1998, 8:101-106.
8. Sekijima Y., Wiseman R.L., Matteson J., Hammarstrom P., Miller S.R., Sawkar A.R., Balch W.E., Kelly J.W. The biological and chemical basis for tissue-selective amyloid disease. Cell 2005, 121:73-85.
9. Connors L.H., Lim A., Prokaeva T., Roskens V.A., Costello C.E. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid 2003, 10:160-184.
10. Jacobson D.R., Pan T., Kyle R.A., Buxbaum J.N. Transthyretin ILE20, a new variant associated with late-onset cardiac amyloidosis. Hum. Mutat. 1997, 9:83-85.
11. Jacobson D.R., Pastore R.D., Yaghoubian R., Kane I., Gallo G., Buck F.S., Buxbaum J.N. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N. Engl. J. Med. 1997, 336:466-473.
12. Davidson M.M., Nesti C., Palenzuela L., Walker W.F., Hernandez E., Protas L., Hirano M., Isaac N.D. Novel cell lines derived from adult human ventricular cardiomyocytes. J. Mol. Cell. Cardiol. 2005, 39:133-147.
13. Choi S., Connelly S., Reixach N., Wilson I.A., Kelly J.W. Chemoselective small molecules that covalently modify one lysine in a non-enzyme protein in plasma. Nat. Chem. Biol. 2010, 6:133-139.
14. Choi S., Reixach N., Connelly S., Johnson S.M., Wilson I.A., Kelly J.W. A substructure 20 combination strategy to create potent and selective transthyretin kinetic stabilizers that prevent amyloidogenesis and cytotoxicity. J. Am. Chem. Soc. 2010, 132:1359-1370.
15. Johnson S.M., Connelly S., Wilson I.A., Kelly J.W. Toward optimization of the linker substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies. J. Med. Chem. 2008, 51:6348-6358.
16. White J.T., Kelly J.W. Support for the multigenic hypothesis of amyloidosis: the binding stoichiometry of retinol-binding protein, vitamin A, and thyroid hormone influences transthyretin amyloidogenicity in vitro. Proc. Natl. Acad. Sci. USA 2001, 98:13019-13024.
17. Jiang X., Smith C.S., Petrassi H.M., Hammarstrom P., White J.T., Sacchettini J.C., Kelly J.W. An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured. Biochemistry 2001, 40:11442-11452.
18. O'Brien J., Wilson I., Orton T., Pognan F. Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur. J. Biochem. 2000, 267:5421-5426.
19. Reixach N., Deechongkit S., Jiang X., Kelly J.W., Buxbaum J.N. Tissue damage in the amyloidoses: transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc. Natl. Acad. Sci. USA 2004, 101:2817-2822.
20. Ikeda S., Nakazato M., Ando Y., Sobue G. Familial transthyretin-type amyloid polyneuropathy in Japan: clinical and genetic heterogeneity. Neurology 2002, 58:1001-1007.
21. Ranlov I., Alves I.L., Ranlov P.J., Husby G., Costa P., Saraiva M.J.M. A Danish kindred with familial amyloid cardiomyopathy revisited: identification of a mutant transthyretinmethionine 111 variant in serum from patients and carriers. Am. J. Med. 1992, 93:3-8.
22. Coelho T., Carvalho M., Saraiva M., Alves I., Almeida M.R., Costa P.P. A strikingly benign evolution of FAP in an individual found to be a compound heterozygote for two TTR mutations: TTR MET 30 and TTR MET 119. J. Rheumatol. 1993, 20:179.
23. Hammarstrom P., Schneider F., Kelly J.W. Trans-suppression of misfolding in an amyloid disease. Science 2001, 293:2459-2462.
24. Lindhagen-Persson M., Vestling M., Reixach N., Olofsson A. Formation of cytotoxic transthyretin is not dependent on inter-molecular disulphide bridges commonly found within the amyloid form. Amyloid 2008, 15:240-245.
25. Sorgjerd K., Klingstedt T., Lindgren M., Kagedal K., Hammarstrom P. Prefibrillar transthyretin oligomers and cold stored native tetrameric transthyretin are cytotoxic in cell culture. Biochem. Biophys. Res. Commun. 2008, 377:1072-1078.
26. Klabunde T., Petrassi H.M., Oza V.B., Raman P., Kelly J.W., Sacchettini J.C. Rational design of potent human transthyretin amyloid disease inhibitors. Nat. Struct. Biol. 2000, 7:312-321.
27. Purkey H.E., Dorrell M.I., Kelly J.W. Evaluating the binding selectivity of transthyretin amyloid fibril inhibitors in blood plasma. Proc. Natl. Acad. Sci. USA 2001, 98:5566-5571.
28. Wenzel E., Somoza V. Metabolism and bioavailability of trans-resveratrol. Mol. Nutr. Food Res. 2005, 49:472-481.
29. Hongo M., Kono J., Yamada H., Misawa T., Tanaka M., Nakatsuka T., Kinoshita O., Okubo S., Sekiguchi M. Doppler echocardiographic assessments of left ventricular diastolic filling in patients with amyloid heart disease. J. Cardiol. 1991, 21:391-401.
30. Sousa M.M., Cardoso I., Fernandes R., Guimaraes A., Saraiva M.J. Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. Am. J. Pathol. 2001, 159:1993-2000.
31. Sousa M.M., Fernandes R., Palha J.A., Taboada A., Vieira P., Saraiva M.J. Evidence for early cytotoxic aggregates in transgenic mice for human transthyretin Leu55Pro. Am. J. Pathol. 2002, 161:1935-1948.
32. Jacobson D.R., Ittmann M., Buxbaum J.N., Wieczorek R., Gorevic P.D. Transthyretin Ile 122 and cardiac amyloidosis in African-Americans: 2 case reports. Tex. Heart Inst. J. 1997, 24:45-52.
33. Hamour I.M., Lachmann H.J., Goodman H.J., Petrou M., Burke M.M., Hawkins P.N., Banner N.R. Heart transplantation for homozygous familial transthyretin (TTR) V122I cardiac amyloidosis. Am. J. Transplant. 2008, 8:1056-1059.
34. Reixach N., Adamski-Werner S.L., Kelly J.W., Koziol J., Buxbaum J.N. Cell based screening of inhibitors of transthyretin aggregation. Biochem. Biophys. Res. Commun. 2006, 348:889-897.
35. Bourgault S., Solomon J.P., Reixach N., Kelly J.W. Sulfated glycosaminoglycans accelerate transthyretin amyloidogenesis by quaternary structural conversion. Biochemistry 2011, 50:1001-1015.
36. Noborn F., O'Callaghan P., Hermansson E., Zhang X., Ancsin J.B., Damas A.M., Dacklin I., Presto J., Johansson J., Saraiva M.J., Lundgren E., Kisilevsky R., Westermark P., Li J.P. Heparan sulfate/heparin promotes transthyretin fibrillization through selective binding to a basic motif in the protein. Proc. Natl. Acad. Sci. USA 2011, 108:5584-5589.